Provided by Tiger Fintech (Singapore) Pte. Ltd.

ASCLETIS-B

8.610
-0.490-5.38%
Volume:4.79M
Turnover:41.78M
Market Cap:8.30B
PE:-26.18
High:9.300
Open:9.110
Low:8.560
Close:9.100
Loading ...

Ascletis Announces First Participants Dosed in U.S. Phase I Clinical Study of Asc50, a Potential Best-in-Class Oral Small Molecule Il-17 Inhibitor for the Treatment of Psoriasis

THOMSON REUTERS
·
18 Jun

Ascletis Pharma Inc. Announces First Participants Dosed in U.S. Phase I Clinical Trial of Potential Best-in-Class Psoriasis Treatment ASC50

Reuters
·
18 Jun

HK Movers | HK's Biotech Shares Soar. JOINN Soars 8%; Fudan-Zhangjiang up 6%; HeartCare up 2%

Tiger Newspress
·
17 Jun

HK Movers | Biotech Stocks Jump. Canbridge Soars 40%; Ascletis Jumps 17%; TYK Medicines Gains 7%; HBM Holdings, Abbisko Up More Than 6%

Tiger Newspress
·
16 Jun

China's Biotech Moment Ignites a 60% Stock Rally That Beats AI

Bloomberg
·
15 Jun

HK Movers|Pharma Shares Rallied. Sino Biopharm Up 13%; Immunothech And Zai Lab Up 5%; Dualitybio And Grand Pharmaup 4%

Tiger Newspress
·
12 Jun

Ascletis Announces Poster Presentations on the Study Results of Asc30 and Asc47 at the 85TH Scientific Sessions of American Diabetes Association (Ada)

THOMSON REUTERS
·
09 Jun

Ascletis Pharma Inc. Announces Poster Presentations on Study Results of GLP-1R Agonist ASC30 and Weight Loss Drug Candidate ASC47 at ADA Scientific Sessions

Reuters
·
09 Jun

HK Movers|Pharma Shares Rallied. CSPC Pharma Up 9%; 3SBio Up 4%; Yihai Up 3%; Genscript Bio And JXR Up 2%.

Tiger Newspress
·
06 Jun

HK Movers|HK Pharma Shares Kept Rally. Zai Lab Up 7%; Hutchmed Up 6%; Immunotech Up 5%

Tiger Newspress
·
05 Jun

BUZZ-Sagimet soars as oral acne drug aces late-stage trial in China

Reuters
·
04 Jun

Sagimet Biosciences Shares Jump 52% Premarket After Oral Acne Drug With Partner Ascletis Met the Main Goals in a Late-Stage Trial

THOMSON REUTERS
·
04 Jun

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat in Treating Moderate-to-Severe Acne

Reuters
·
04 Jun

HK Movers|Pharma Shares Jumped. Innovent Bio Up 15%; Zai Lab Up 5%; Junshi Bio And CSPC Pharma Up 4%

Tiger Newspress
·
04 Jun

Ascletis Pharma Announces Successful Phase III Trial of Denifanstat, a Groundbreaking Oral FASN Inhibitor for Acne Treatment

Reuters
·
04 Jun

Ascletis Announces Phase Iii Trial of Denifanstat (Asc40), a First-in-Class, Once-Daily Oral Fasn Inhibitor for Acne, Meets All Endpoints

THOMSON REUTERS
·
04 Jun

Ascletis Pharma Inc - Announces Phase Iii Trial of Denifanstat Meets All Endpoints

THOMSON REUTERS
·
04 Jun

HK Movers|HK's Pharma Shares Jumped. Medlive Up 8%; Sihuan Pharm And Junshi Bio Up 7%; Pharmaron And Fosun Pharma Up 5%

Tiger Newspress
·
03 Jun

Ascletis Pharma Faces Legal Setback with Seven-Year Exclusion Order for ASC41 and ASC43F Drugs

Reuters
·
30 May

HK Movers | Biopharmaceutical Stocks Jump With SinoMab BioScience up 18%

Tiger Newspress
·
30 May